MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Operating Income 2011-2026 | RNLX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.6 M | -42.2 M | -53.2 M | -31.9 M | -10.3 M | -42.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -53.2 M | -34.9 M |
Quarterly Operating Income Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.09 M | - | -6.55 M | -8.64 M | -8.89 M | - | -10.9 M | -9.65 M | -11.7 M | - | -14.5 M | -13.8 M | - | - | -8.07 M | -8.61 M | - | - | - | - | - | - | - | - | - | -567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -14.5 M | -8.84 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 24.58 | 1.91 % | $ 99.4 M |  Israel |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.12 | -0.88 % | $ 1.42 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 28.4 | -1.41 % | $ 306 M |  China |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 106.01 | 0.82 % | $ 4.18 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.26 | - | $ 319 M | Israel |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 23.02 | 0.04 % | $ 696 M | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 209.34 | 0.95 % | $ 23.2 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 30.02 | 3.73 % | $ 834 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.18 | 2.08 % | $ 1.03 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 209.79 | -0.58 % | $ 153 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
912 M | $ 72.99 | -0.38 % | $ 28.5 B | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.46 | 0.07 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 96.45 | 2.15 % | $ 12.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 287.1 | 0.62 % | $ 24.1 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 166.77 | 1.98 % | $ 8.27 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 104.81 | 0.14 % | $ 8.65 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.77 | 0.53 % | $ 2.02 M | USA |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 648.66 | 4.1 % | $ 52.2 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 123.46 | 2.42 % | $ 19.6 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 164.94 | 1.75 % | $ 28.4 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 31.48 | 0.82 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
-34.5 M | $ 13.28 | 3.99 % | $ 1.72 B | USA |
 |
Natera
NTRA
|
-541 M | $ 209.72 | 0.18 % | $ 20.6 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 73.43 | 0.01 % | $ 5.08 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.11 | 0.49 % | $ 4.85 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 8.71 | 0.58 % | $ 546 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 442.92 | -0.46 % | $ 12.8 B | USA |